Camilo de la
Fuente-Sandoval1, Pablo L. Ortiz2, Xiangling Mao3,
Patricia Alavarado-Alanis4, Oscar Rodrguez-Mayoral5,
Francisco Reyes-Madrigal4, Ariel Graff-Guerrero6,
Rodolfo Solis-Vivanco7, Rafael Favila8, Dikoma C.
Shungu3
1Neuropsychiatry
& Laboratory of Experimental Psychiatry, Instituto Nacional de Neurologa
y Neurociruga (INNN), Mexico City, Distrito Federal, Mexico; 2Education,
INNN, Mexico City, Distrito Federal, Mexico; 3Radiology, Weill
Cornell Medical College, New York, NY, United States; 4Laboratory
of Experimental Psychiatry, INNN, Mexico City, Distrito Federal, Mexico; 5Early
Psychosis Intervention, Hospital Fray Bernardino Alvarez, Mexico City,
Distrito Federal, Mexico; 6Multimodal Neuroimaging Schizophrenia
Group, Centre for Addiction and Mental Health, Toronto, ON, Canada; 7Laboratory
of Neuropsychology, INNN, Mexico City, Distrito Federal, Mexico; 8MR
Advanced Applications, GE Healthcare, Mexico City, Distrito Federal, Mexico
This study used 1H MRS to measure and compare brain GABA and glutamatergic compound (Glx) levels in antipsychotic-nave schizophrenia patients during first-episode psychosis (FEP) and age- and sex-matched healthy control (HC) subjects, and found regional elevations or strong trend-level elevations of both neurotransmitters in the FEP subjects.